Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 12/20 | 0.61 |
| ▸ | PYGL | P06737 | 10/20 | 0.61 |
| ▸ | PYGM | P11217 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375242 | 1.00 | CYP51A1 (0.61) | CYP51A1PYGLPYGM | |
| SCHEMBL2606832 | 0.90 | CYP51A1 (0.61) | CYP51A1PYGLPYGM | |
| SCHEMBL14375243 | 0.90 | CYP51A1 (0.61) | CYP51A1PYGLPYGM | |
| SCHEMBL2606837 | 0.90 | CYP51A1 (0.61) | CYP51A1PYGLPYGM | |
| SCHEMBL2107376 | 0.89 | CYP51A1 (0.78) | CYP51A1PYGLPYGM | |
| SCHEMBL2606967 | 0.87 | CYP51A1 (0.59) | CYP51A1PYGLPYGM | |
| SCHEMBL2606902 | 0.87 | CYP51A1 (0.61) | CYP51A1PYGLPYGM | |
| SCHEMBL2606964 | 0.86 | CYP51A1 (0.56) | CYP51A1PYGLPYGM | |
| SCHEMBL2606918 | 0.85 | CYP51A1 (0.71) | CYP51A1PYGLPYGM | |
| SCHEMBL2109119 | 0.85 | CYP51A1 (0.71) | CYP51A1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CYP51A1 598/4885PYGL 1/4885PYGM 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.